
Opinion|Videos|August 12, 2024
ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer
A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What future research is needed to further support decision-making when using CDK4/6 inhibitors for early breast cancer?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Boosting RSV Vaccination in Older Adults Could Save Thousands
4
Cancer Care in Transition: Navigating Breakthrough Therapies Amid Economic Strain
5














































